

# SARS-CoV-2 infection in an advanced Rheumatoid Arthritis patient

**Ahmadreza Bazmjoo**

Jahrom University of Medical Sciences, Jahrom, Iran

**Mohammad Aref Bagherzadeh**

Jahrom University of Medical Sciences, Jahrom, Iran

**Farida Farahmandpoor**

Fasa University of Medical Sciences, Fasa, Iran

**Rahim Raoofi**

Jahrom University of Medical Sciences, Jahrom, Iran

**Amir Abdoli** (✉ [a.abdoli25@gmail.com](mailto:a.abdoli25@gmail.com))

Jahrom University of Medical Sciences, Jahrom, Iran <https://orcid.org/0000-0003-4326-4586>

---

## Case Report

**Keywords:** SARS-CoV-2, COVID-19, Rheumatoid Arthritis, immunosuppressive therapy

**Posted Date:** November 18th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-40731/v2>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on September 18th, 2020. See the published version at <https://doi.org/10.1111/apm.13080>.

Letter to the Editor (Case report)

## **SARS-CoV-2 infection in an advanced Rheumatoid Arthritis patient**

Short title: COVID-19 and Rheumatoid Arthritis

### *Authors and affiliations*

**Ahmadreza Bazmjoo <sup>1</sup>, Mohammad Aref Bagherzadeh <sup>1</sup>, Farida Farahmandpoor <sup>2</sup>, Rahim Raoofi <sup>3</sup>,  
Amir Abdoli <sup>4</sup>**

1. Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran
2. Control Disease Department, Department of Health, Fasa University of Medical Sciences, Fasa,  
Iran
3. Department of Infectious Diseases, Jahrom University of Medical Sciences, Jahrom, Iran
4. Zoonoses Research Center and Department of Parasitology and Mycology, Jahrom University of  
Medical Sciences, Jahrom, Iran

**Keywords:** SARS-CoV-2, COVID-19, Rheumatoid Arthritis, immunosuppressive therapy.

Number of figures: 1

Number of words: 715

Corresponding Author:

**Amir Abdoli, PhD**

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/apm.13080](https://doi.org/10.1111/apm.13080)

This article is protected by copyright. All rights reserved

Email: a.abdoli25@gmail.com; a.abdoli@jums.ac.ir

Orchid ID: 0000-0003-4326-4586

Tel: +98 9127144223

*Jahrom University of Medical Sciences, POBox 74148-46199, Ostad Motahari Ave, Jahrom, Iran.*

Dear Editor,

In late 2019, pneumonia due to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, which has immediately spread around the world. The major clinical manifestations of COVID-19 include a range from asymptomatic presentation to acute respiratory distress syndrome (ARDS) [1]. Rheumatoid Arthritis (RA) patients usually managed with immunosuppressive agents, hence, they are at a higher risk of infections [2]. However, limited data are available about the severe case of COVID-19 in RA patients [3-7]. Here we present a complicated case of SARS-CoV-2 infection in a female RA patient.

*Case presentation:* The patient was a 49 years-old woman with a history of 15 years RA. She has received conventional treatments (first-line treatments) as conventional Disease-modifying antirheumatic drugs (csDMARDs) medication (Ebetrex (methotrexate) 15 mg/week Thursdays and Fridays, Sulfasazin 1000 mg/day), Ipravent 20 mg, vitamin D-calcium (1 tab/day) and corticosteroids (Nisopred 5 mg/day).

She admitted to the hospital (Valiye Asr hospital, Fasa, Iran) at 11, March 2020 with a dry cough, fever, myalgia, respiratory distress, dizziness and nausea. Though O<sub>2</sub> Saturation (SPO<sub>2</sub>%) was low (64%) on the admission, the O<sub>2</sub> nebulizer administered (O<sub>2</sub> 5 lit/min) which resulted in the correction of O<sub>2</sub> Saturation (87%). Four days before admission, she had only dry cough without other symptoms. She declared no sign of reduced smell and taste senses. Before admission, she had a history of contact with her two daughters, her husband, and 1-year-old grandchildren, that all of them were positive for COVID-19 by real-time PCR test. She was the only member of her family with severe respiratory problems that needed to be hospitalized (and also the only person with RA in her family), while the rest of the family showed mild symptoms and quarantined at home. The Chest x-rays on the first day of hospitalization showed pneumonia signs alongside with

bilateral ground-glass pattern, vascular dilation, and traction bronchiectasis in the middle and secondary lobes (Figure 1). Positive real-time PCR tests confirmed the SARS-CoV-2 infection. Laboratory findings on admission was a very low WBC count and reduced number of platelets, elevated ESR and PT.

Therapy with Hydroxychloroquine was started on the 1<sup>st</sup> day and continued for 10 days. Oseltamivir was added on the 2<sup>nd</sup> day and continued for 6 days. The patient's nausea was controlled by Ranitidine, Ondansetron, and Pantoprazole. Kaletra (Lopinavir/Ritonavir 200-50 mg/day and night 2 tab each) was added to the antiviral regimen on the 4<sup>th</sup> day, continued as the main antiviral medication for 7 days until symptoms relieved. A cluster of antibiotics was prescribed for the first week because of low WBC count and suppressed immunity to prevent secondary infection. In the following, she was treated with a period of Levofloxacin medication in home quarantine (day 14 till 27). Theophylline G and O2 Nebulizer treatment helped to support the airway and reduce the respiratory symptoms. As laboratory findings and symptoms demonstrate, the patient's condition was by the end of 1st week worsened. The WBC and RBC count were reduced. Chest CT scans at the 2<sup>nd</sup> week revealed the destructive effects of inflammation of the infection (Figure 1). Due to the laboratory findings and symptoms were more similar to the COVID-19 cytopenia, we decided to redesign the treatment. So, the DMARDs and immunosuppressant treatment were omitted. We then discontinued the Ebtrex and Nisopred at the 2<sup>nd</sup> week by dose reduction, only Sulfasalazine was continued. This strategy led to increased WBC count and altered hematologic factors (Supplementary table 1). By reducing the symptoms, the patient was discharged with a stable condition and quarantined for 14 days at home. Her real-time PCR was negative on day 27. The last chest CT scans and X rays showed a significant reduction in GGO on day 35 (Figure 1).

Immunosuppressive medication in RA patients (*e.g.*, csDMARDs and corticosteroids) in the course of SARS-CoV-2 infection may be as a double-edged sword [8]. Managing the RA disease with the lowest possible dose of csDMARDs besides treatment of SARS-CoV-2 could be an effective strategy for treatment of COVID-19 in RA patients. The results of this case have shown that a gradual reduction of immunosuppressive drugs could helped to decline the disease severity.

## ABBREVIATIONS

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

COVID-19: coronavirus disease 2019

ARDS: acute respiratory distress syndrome

RA: Rheumatoid Arthritis

DMARDs: Disease-modifying anti-rheumatic drugs

GGO: ground glass opacity

### **ETHICS STATEMENTS**

Informed consent was obtained from the participant for the publication of this case report. The study approved by the Ethics Committee of Jahrom University of Medical Sciences, Jahrom, Iran (Approval ID: IR.JUMS.REC.1399.043).

### **DATA AVAILABILITY STATEMENT**

All datasets generated for this study are available.

**Funding:** This study was not receiving any funding.

**Conflicts of Interest:** The authors declare no competing interests.

**Acknowledgments:** The authors sincerely appreciate doctors, nurses, and laboratory personals of Jahrom and Fasa Universities of Medical Sciences for their tireless efforts in this crisis. We also thank the patient for her participation.


### **AUTHOR CONTRIBUTIONS**

AB, MAB and AA designed the study. AB and MAB wrote the draft of the manuscript. AB and FF collected data and performed analyses. RR, FF, and AA supervised the study. AA revised the manuscript for submission.


### **References**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506. doi: [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
2. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. *Nat Rev Dis Prim*. 2018;4(1):18001. doi: 10.1038/nrdp.2018.1.
3. Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. *Lancet Rheumatol*. 2020;2(5):e250-e3.
4. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. *Ann Rheum Dis*. 2020;79(5):667-8.
5. Moiseev S, Avdeev S, Brovko M, Yavorovskiy A, Novikov PI, Umbetova K, et al. Rheumatic diseases in intensive care unit patients with COVID-19. *Ann Rheum Dis*. 2020;Published Online First:annrheumdis-2020-217676. doi: 10.1136/annrheumdis-2020-217676.
6. López-González M-d-C, Peral-Garrido ML, Calabuig I, Tovar-Sugrañes E, Jovani V, Bernabeu P, et al. Case series of acute arthritis during COVID-19 admission. *Ann Rheum Dis*. 2020;Published Online First:annrheumdis-2020-217914. doi: 10.1136/annrheumdis-2020-217914.
7. Mendel A, Bernatsky S, Thorne JC, Lacaille D, Johnson SR, Vinet É. Hydroxychloroquine shortages during the COVID-19 pandemic. *Annals of the Rheumatic Diseases*. 2020.
8. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: Faraway, so close! *Autoimmun Rev*. 2020;19(5):102523. doi: <https://doi.org/10.1016/j.autrev.2020.102523>.

**Figures 1.** **A:** Chest x-rays on day of hospitalization showed transparency and bilateral lung involvement in the middle and secondary lobes. **B** (Chest x-ray; coronal section) and **C** (CT scan; axial section): on day of hospitalization showed transparency GGO and bilateral lung involvement in the middle and lower lobes. **D, E,** (CT scans) **and F** (Chest x-ray): at day 14 showed worsening and increased symptoms of lung involvement, GGO, consolidation and visible intralobular lines (crazy paving pattern). **G, H** (Chest x-ray) **and I** (CT scans): on day 35 showed a significant reduction in GGO.



# Figures



**Figure 1**

A: Chest x-rays on day of hospitalization showed transparency and bilateral lung involvement in the middle and secondary lobes. B (Chest x-ray; coronal section) and C (CT scan; axial section): on day of hospitalization showed transparency GGO and bilateral lung involvement in the middle and lower lobes.

D, E, (CT scans) and F (Chest x-ray): at day 14 showed worsening and increased symptoms of lung involvement, GGO, consolidation and visible intralobular lines (crazy paving pattern). G, H (Chest x-ray) and I (CT scans): on day 35 showed a significant reduction in GGO.

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplemental.RACOV1D19.pdf](#)